Project Grant R21AI180334

Award Date 7/5/24
Completion Date 5/31/26
Dollars Obligated $940K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Little Rock, AR 72202, USA
Similar Awards
This Project Grant award of $838,320.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The purpose of the grant is to conduct research to define the genetic network in the fungus Aspergillus fumigatus that mediates its ability to cause invasive aspergillosis infections, particularly in the context of patients receiving Bruton's tyrosine kinase (BTK) inhibitor therapies for cancer. The...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 - Allergy and Infectious Diseases Research program provides $170,000.00 to Prokaryotics Incorporated, a pharmaceutical research company, to perform structure-based design of novel antifungal inhibitors targeting the glycosylphosphatidylinositol (GPI) ethanolamine phosphate transferase, MCD4. The research aims to develop mechanistically novel antifungal agents to address...
This Project Grant award of $750,815, provided by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research), supports research aimed at developing novel anti-infective strategies to treat pulmonary mucormycosis, a deadly invasive fungal infection. The key objectives are to: 1) examine the role of the host cell hypoxia-response pathway, specifically the protein ANGPTL4, in the pathogenesis of mucormycosis and explore its therapeutic...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $262,098 to the University of Wisconsin-Madison to develop and characterize human induced pluripotent stem cell (iPSC)-derived neutrophil therapies against pathogenic Aspergillus fungi. The award will fund research to assess the ability of these engineered neutrophils to inhibit the growth of clinically relevant...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $871,154 to Virginia Polytechnic Institute & State University (Virginia Tech) to conduct research on the molecular mechanisms that enable the fungal pathogen Aspergillus fumigatus to respond to the antifungal drug caspofungin. The overarching goal is to determine how the septin cytoskeleton in A. fumigatus mediates...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $494,696 to The University of Texas Health Science Center at San Antonio to conduct research on translational control mechanisms regulating Candida albicans morphology, stress responses, and virulence. The research aims to determine how the ASC1 and EIF4E-binding proteins function together to modulate the EIF4F...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $119,082 to Brigham & Women's Hospital Inc. to conduct research on adaptive immunity to the fungus Aspergillus during neutropenia. The research aims to determine how neutrophils influence the development of adaptive immunity to Aspergillus, a life-threatening respiratory infection, in...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $558,747 to Texas Tech University Health Sciences Center (TTUHSC) to conduct research on a novel link between calcineurin, amino acid permease, and protein kinase A in the virulence of the fungus Mucor, which causes the life-threatening condition mucormycosis. The 5-year project aims to identify key transcription...
The federal Project Grant award R21AI190747, totaling $249,749.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program. The grant supports research by the University of Iowa to develop a new approach for analyzing the transcriptional control of virulence in the human fungal pathogen Aspergillus fumigatus. The research aims to enable time-dependent proteolytic removal of key transcription...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $689,068 to the University of Cincinnati to establish ex vivo growth systems for the fungal genus Pneumocystis, which causes a life-threatening pneumonia in immunodeficient individuals. The key objectives are to: 1) Use metabolomics and flux balance analysis to identify critical nutrients for growing the surrogate...

PKA-DEPENDENT AUTOPHAGY CONTROL IN ASPERGILLUS FUMIGATUS PATHOGENESIS - INVASIVE ASPERGILLOSIS (IA), CAUSED BY THE FUNGUS ASPERGILLUS FUMIGATUS, IS A LEADING INFECTIOUS CAUSE OF DEATH IN IMMUNOCOMPROMISED PATIENTS. A SIGNIFICANT BARRIER TO DECIPHERING THE MECHANISMS OF PATHOGENESIS AND DEVELOPING EFFECTIVE ANTIFUNGALS IS A LACK OF UNDERSTANDING OF THE REGULATION OF A. FUMIGATUS GROWTH LEADING TO INVASIVE DISEASE. CELLULAR RECYCLING MEDIATED VIA AUTOPHAGY-ASSOCIATED PROTEINS IS A KEY CATABOLIC PATHWAY AND CRITICAL TO INVASIVE FUNGAL GROWTH AND VIRULENCE IN THE WELL-KNOWN NUTRIENT-LIMITED HOST ENVIRONMENT. PROTEIN KINASE A (PKA) IS VITAL FOR GROWTH AND VIRULENCE OF NUMEROUS FUNGAL PATHOGENS. HOWEVER, THE UNDERLYING BASIS FOR ITS REGULATION OF PATHOGENESIS REMAINS POORLY UNDERSTOOD IN ANY SPECIES. OUR A. FUMIGATUS PKA-DEPENDENT WHOLE PROTEOME AND PHOSPHOPROTEOME STUDIES EMPLOYING ADVANCED MASS SPECTROSCOPIC (MS) APPROACHES IDENTIFIED NUMEROUS PREVIOUSLY UNDEFINED PKA-REGULATED PROTEINS IN CATABOLIC PATHWAYS. PRELIMINARY CHARACTERIZATION OF TWO SUCH NOVEL DIRECT PKA TARGET PROTEINS, ATG24 AND NOT4, DEMONSTRATED THEIR REQUIREMENT FOR A. FUMIGATUS VIRULENCE AND ALSO REVEALED FUNCTIONAL IMPORTANCE OF PKA-DEPENDENT PHOSPHORYLATION OF SPECIFIC TARGET SITES. WE HAVE IDENTIFIED AND PRIORITIZED MORE THAN 30 AUTOPHAGY-ASSOCIATED PROTEINS AS LIKELY NOVEL PKA-REGULATED EFFECTORS, AND WILL NOW CHARACTERIZE THE TOP 6 PRIORITY PROTEINS WITH REGARD TO THEIR ROLES IN FUNGAL GROWTH AND PATHOGENESIS, AS WELL AS THEIR REGULATION BY PKA. OUR OVERALL OBJECTIVE IS TO LEVERAGE OUR ROBUST PKA WHOLE PROTEOMIC AND PHOSPHOPROTEOMIC DATA TO DEFINE FUNGAL-SPECIFIC MECHANISMS OF PKA CONTROL OVER AUTOPHAGY FUNCTION AND VALIDATE THESE PKA-REGULATED EFFECTORS' NOVEL CONTRIBUTIONS TO FUNGAL VIRULENCE. IN AIM 1, WE WILL DEFINE PKA CONTROL OVER AUTOPHAGY BY VALIDATING PKA-DEPENDENT PHOSPHORYLATION OF PRIORITIZED PHOSPHOREGULATED EFFECTORS VIA MS ANALYSIS AND EXPRESSION-REGULATED EFFECTORS VIA QRT-PCR. WE WILL CHARACTERIZE THE ROLE OF EACH PKA EFFECTOR IN FUNGAL GROWTH AND STRESS RESPONSES THROUGH DELETION AND PHOSPHOSITE MUTAGENESIS APPROACHES. WE WILL ALSO PERFORM STRUCTURAL ELUCIDATION OF PKA-EFFECTOR PHOSPHOREGULATION AND FUNCTION USING MOLECULAR MODELING AND MOLECULAR DYNAMICS SIMULATIONS. IN AIM 2, WE WILL VALIDATE THE ROLES OF PKA-REGULATED AUTOPHAGY PROTEINS IN VIRULENCE AND HOST-PATHOGEN INTERACTION USING OUR MURINE MODEL OF INVASIVE ASPERGILLOSIS TO ASSESS THEIR IMPACT ON MORTALITY, FUNGAL BURDEN AND HOST LUNG TISSUE DAMAGE VIA HISTOLOGICAL ANALYSIS. WE WILL ALSO ASSESS THE IMPACT OF PKA-REGULATED PROTEINS ON BOTH THE PATHOGEN AND HOST RESPONSE TO INFECTION BY EXPRESSION PROFILING OF A. FUMIGATUS AUTOPHAGY MARKER GENES, AS WELL AS SIMULTANEOUS EXAMINATION OF THE HOST IMMUNE CYTOKINE RESPONSE DURING INFECTION WITH WILD-TYPE AND MUTANT STRAINS. PKA REGULATES CATABOLIC PROCESSES CRITICAL TO FUNGAL GROWTH, YET AN UNDERSTANDING OF PKA REGULATION OF AUTOPHAGY PATHWAYS IS LACKING IN ANY ORGANISM. WE WILL DEFINE NOVEL PKA-DEPENDENT REGULATION OF NEWLY- IDENTIFIED FUNGAL-SPECIFIC AUTOPHAGY-ASSOCIATED PROTEINS AND PROVIDE CRITICAL INSIGHT INTO FUTURE EXPLOITATION OF PKA-DEPENDENT CONTROL OVER A. FUMIGATUS DISEASE.

Posted 7/5/24, 12:00 AM